



RACIAL AND ETHNIC DISPARITIES IN OUTCOMES AMONG PATIENTS WITH TP53-MUTATED AML: A PROPENSITY-MATCHED REAL-WORLD ANALYSIS

H. Hotchandani¹, I. Deshmukh¹, A. Patel¹, J. Malhotra¹, V. Patel¹, R. Desai³, D. Parekh¹, V. Aggarwal¹, S. Shah¹, K. Desai¹

- 1. Division of Hematology/Oncology, SUNY Upstate Medical University, Syracuse, NY, USA
- 2. University of Texas MD Anderson Cancer Center, Houston, Texas, USA
- 3. Orlando College of Osteopathic Medicine, Winter Garden, FL, USA



INTRODUCTION

TP53-mutated acute myeloid leukemia (AML) is associated with poor prognosis and adverse clinical outcomes, yet racial and ethnic disparities among these patients remain poorly characterized.

AIM

To evaluate racial and ethnic disparities in survival, transplant and venetoclax utilization, healthcare resource use, and infectious complications among patients with TP53-mutated AML, comparing Hispanic vs non-Hispanic and non-Hispanic White vs non-Hispanic Black patients.


METHOD

- Retrospective cohort study using TriNetX, January 2000–January 2026
- Adult patients with AML and documented TP53 mutation/variant testing
 - Two 1:1 propensity-matched analyses: Hispanic vs non-Hispanic, and non-Hispanic White vs non-Hispanic Black


CONCLUSIONS

Significant disparities exist in TP53-mutated AML, particularly regarding stem cell transplant utilization among Black patients. Hispanic patients demonstrated a trend toward inferior survival despite similar treatment patterns.

RESULTS



A. 1-Year Survival — Hispanic vs Non-Hispanic (log-rank p=0.06)



B. Stem Cell Transplant — White vs Black (p<0.001)

Outcome	Comparison	Result (%)	p-value	Significance
Mortality	Hispanic vs Non-Hispanic	23.2 vs 14.8	0.06	Trend: Hispanic worse
SCT	Hispanic vs Non-Hispanic	31.7 vs 36.6	0.38	NS
Venetoclax use	Hispanic vs Non-Hispanic	18.3 vs 25.4	0.15	NS
ICU admission	Hispanic vs Non-Hispanic	19.0 vs 16.2	0.53	NS
Hospitalization	Hispanic vs Non-Hispanic	69.0 vs 73.2	0.43	NS
Infections	Hispanic vs Non-Hispanic	59.9 vs 61.3	0.81	NS
Mortality	White vs Black	29.8 vs 29.1	0.92	NS
SCT	White vs Black	28.7 vs 15.2	<0.001	White higher
Hospitalization	White vs Black	81.2 vs 74.8	0.07	Trend: Black higher
Venetoclax use	White vs Black	36.2 vs 29.1	0.07	Trend: White Higher